Mylaxen
Brand names,
Mylaxen
Analogs
Mylaxen
Brand Names Mixture
Mylaxen
Chemical_Formula
C36H42Br2N2
Mylaxen
RX_link
No information avaliable
Mylaxen
fda sheet
Mylaxen
msds (material safety sheet)
Mylaxen
Synthesis Reference
No information avaliable
Mylaxen
Molecular Weight
662.54 g/mol
Mylaxen
Melting Point
153.5 oC
Mylaxen
H2O Solubility
No information avaliable
Mylaxen
State
Solid
Mylaxen
LogP
-0.06
Mylaxen
Dosage Forms
Solution (injectable)
Mylaxen
Indication
Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.
Mylaxen
Pharmacology
Hexafluorenium is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery.
Mylaxen
Absorption
No information avaliable
Mylaxen
side effects and Toxicity
LD50 = 280 mg/kg (mouse, oral)
Mylaxen
Patient Information
No information avaliable
Mylaxen
Organisms Affected
Humans and other mammals